**Supplementary Table 3: Clinical trials of A2AR inhibitors**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **NCT**  | **Project title** | **Conditions** | **Interventions** | **Sponsor** | **Phases** |
| [NCT03207867](https://ClinicalTrials.gov/show/NCT03207867) | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma | NSCLC, Non Small Cell Lung Cancer|RCC, Renal Cell Cancer|Pancreatic Cancer|Urothelial Cancer|Head and Neck Cancer|DLBCL, Diffused Large B Cell Lymphoma|MSS, Microsatellite Stable Colon Cancer|TNBC, Triple Negative Breast Cancer|Melanoma|mCRPC, Metastatic Castration Resistant Prostate Cancer | NIR178 +/- PDR001 | Novartis  | Phase 2 |
| [NCT05501054](https://ClinicalTrials.gov/show/NCT05501054) | Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma. | Renal Cell Carcinoma | Ipilimumab +/- Nivolumab +/- Ciforadenant | M.D. Anderson Cancer Center | Phase 1 Phase 2 |
| [NCT04280328](https://ClinicalTrials.gov/show/NCT04280328) | Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma | Multiple Myeloma | Ciforadenant +/- daratumumab | Corvus. | Phase 1 |
| [NCT04089553](https://ClinicalTrials.gov/show/NCT04089553) | An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer | Prostate Cancer|Metastatic Castration-Resistant Prostate Cancer (mCRPC) | AZD4635 +/- Oleclumab +/- Durvalumab | AstraZeneca | Phase 2 |
| **NCT**  | **Project title** | **Conditions** | **Interventions** | **Sponsor** | **Phases** |
| [NCT02403193](https://ClinicalTrials.gov/show/NCT02403193) | Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | Non-small Cell Lung Cancer (NSCLC) | PBF-509\_80 mg +/- PBF-509\_160 mg +/- PBF-509\_320 mg +/- PBF-509\_640 mg +/- Combo PBF-509 (160 mg) + PDR001 +/- Combo PBF-509 (320 mg) + PDR001 +/- Combo PBF-509 (640 mg) + PDR001 +/- RP2D (PBF-509+PDR001)\_immuno naive +/- Experimental: RP2D (PBF-509+PDR001)\_immuno treated | Palobiofarma SLNovartis|H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| [NCT02655822](https://ClinicalTrials.gov/show/NCT02655822) | Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers | Renal Cell Cancer|Metastatic Castration Resistant Prostate Cancer | Ciforadenant +/- Ciforadenant + atezolizumab | Corvus Genentech, Inc. | Phase 1 |
| [NCT04895748](https://ClinicalTrials.gov/show/NCT04895748) | DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies | Carcinoma, Renal Cell | DFF332 +/- RAD001 +/- PDR001 +/- NIR178 | Novartis  | Phase 1 |
| [NCT03720678](https://ClinicalTrials.gov/show/NCT03720678) | A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies | GastroEsophageal Cancer|Colorectal Cancer | etrumadenant +/- mFOLFOX | Arcus. | Phase 1 |
| **NCT**  | **Project title** | **Conditions** | **Interventions** | **Sponsor** | **Phases** |
| [NCT03549000](https://ClinicalTrials.gov/show/NCT03549000) | A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. | Non-small Cell Lung Cancer (NSCLC)|Triple Negative Breast Cancer (TNBC)|Pancreatic Ductal Adenocarcinoma (PDAC)|Colorectal Cancer Microsatellite Stable (MSS)|Ovarian Cancer|Renal Cell Carcinoma (RCC)|Metastatic Castration Resistant Prostate Cancer (mCRPC) | NZV930 +/- PDR001 +/- NIR178 | Novartis  | Phase 1 |
| [NCT03629756](https://ClinicalTrials.gov/show/NCT03629756) | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | Non-small Cell Lung Cancer|Squamous Cell Carcinoma of the Head and Neck|Breast Cancer|Colorectal Cancer|Melanoma|Bladder Cancer|Ovarian Cancer|Endometrial Cancer|Merkel Cell Carcinoma|GastroEsophageal Cancer|Renal Cell Carcinoma|Castration-resistant Prostate Cancer | Etrumadenant +/- Zimberelimab | Arcus  | Phase 1 |
| [NCT05177770](https://ClinicalTrials.gov/show/NCT05177770) | Study of SRF617 With AB928 (Etrumadenent) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer | Metastatic Castration-resistant Prostate Cancer|Prostate Cancer | SRF617 +/- etrumadenant +/- zimberelimab | Surface OncologyArcus  | Phase 2 |
| **NCT**  | **Project title** | **Conditions** | **Interventions** | **Sponsor** | **Phases** |
|  |  |  |  |  |  |
| [NCT04262856](https://ClinicalTrials.gov/show/NCT04262856) | Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer | Non Small Cell Lung Cancer|Nonsquamous Non Small Cell Lung Cancer|Squamous Non Small Cell Lung Cancer|Lung Cancer | Zimberelimab +/- Domvanalimab +/- Etrumadenant | Arcus Gilead Sciences | Phase 2 |
| [NCT04892875](https://ClinicalTrials.gov/show/NCT04892875) | A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers | Head and Neck Cancer|Squamous Cell Carcinoma of Head and Neck|Oral Cavity Squamous Cell Carcinoma|Oral Cavity Cancer|Oropharynx Cancer|Oropharynx Squamous Cell Carcinoma|Larynx Cancer|Pharynx Cancer|Hypopharynx Cancer|Hypopharynx Squamous Cell Carcinoma | Zimberelimab +/- Etrumadenant +/- Cisplatin +/- Radiation: Radiation | Jennifer Choe|Arcus Biosciences, Vanderbilt-Ingram Cancer Center | Phase 1 |
| [NCT03719326](https://ClinicalTrials.gov/show/NCT03719326) | A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies | TNBC - Triple-Negative Breast Cancer|Ovarian Cancer | Etrumadenant +/- IPI-549 +/- Pegylated liposomal doxorubicin (PLD) +/- nanoparticle albumin-bound paclitaxel (NP) | Arcus Infinity Pharmaceuticals | Phase 1 |
| [NCT03381274](https://ClinicalTrials.gov/show/NCT03381274) | Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study | Carcinoma, Non-Small-Cell Lung | Oleclumab +/- Osimertinib +/- AZD4635 | MedImmune LLC | Phase 1 Phase 2 |
| **NCT**  | **Project title** | **Conditions** | **Interventions** | **Sponsor** | **Phases** |
| [NCT04969315](https://ClinicalTrials.gov/show/NCT04969315) | TT-10 as a Single Agent in Subjects With Advanced Selected Solid Tumors | Renal Cell Cancer|Castrate Resistant Prostate Cancer|Non Small Cell Lung Cancer | TT-10 | Tarus  | Phase 1 Phase 2 |
| [NCT03846310](https://ClinicalTrials.gov/show/NCT03846310) | A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer | Non Small Cell Lung Cancer Metastatic|Non Small Cell Lung Cancer|Nonsquamous Nonsmall Cell Neoplasm of Lung|Sensitizing EGFR Gene Mutation | Etrumadenant +/- Zimberelimab +/- Carboplatin +/- Pemetrexed +/- Pembrolizumab | Arcus IncGilead Sciences | Phase 1 |
| [NCT04381832](https://ClinicalTrials.gov/show/NCT04381832) | Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer | Prostatic Neoplasms, Castration-Resistant|Androgen-Resistant Prostatic Neoplasms|Castration Resistant Prostatic Neoplasms|Prostatic Cancer, Castration-Resistant | Etrumadenant +/- Zimberelimab +/- Quemliclustat +/- Enzalutamide +/- Docetaxel +/- SG | Arcus Gilead Sciences | Phase 1 Phase 2 |
| [NCT04660812](https://ClinicalTrials.gov/show/NCT04660812) | Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations  | Metastatic Colorectal Cancer | etrumadenant +/- zimberelimab +/- mFOLFOX-6 regimen +/- bevacizumab +/- regorafenib +/- AB680 | Arcus Gilead Sciences | Phase 1 Phase 2 |
|  |  |  |  |  |  |